This article is a correction to:
Editorial: Targeting DNA damage response to enhance antitumor innate immunity in radiotherapy
Victoria M. Valvo1,2
Emanuele Vitale3,4
Marco Tigano4*
Rachel Evans5,6*
Meredith A. Morgan1*
Qiang Zhang1*- 1Department of Radiation Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States
- 2Cancer Biology Program, University of Michigan, Ann Arbor, MI, United States
- 3Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
- 4MitoCare Center, Department of Pathology and Genomic Medicine, Thomas Jefferson University, Philadelphia, PA, United States
- 5Richard Dimbleby Department of Cancer Research, Randall Division & Division of Cancer Studies, Kings College London, London, United Kingdom
- 6Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
A corrigendum on
Editorial: Targeting DNA damage response to enhance antitumor innate immunity in radiotherapy
by Valvo VM, Vitale E, Tigano M, Evans R, Morgan MA and Zhang Q (2023). Front. Oncol. 13:1257622. doi: 10.3389/fonc.2023.1257622
In the published article, an author name was incorrectly written as Victoria Valvo. The correct spelling is Victoria M. Valvo.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: radiotherapy, DNA damage response, immunotherapy, innate immunity, tumor microenvironment
Citation: Valvo VM, Vitale E, Tigano M, Evans R, Morgan MA and Zhang Q (2024) Corrigendum: Editorial: Targeting DNA damage response to enhance antitumor innate immunity in radiotherapy. Front. Oncol. 14:1424895. doi: 10.3389/fonc.2024.1424895
Received: 28 April 2024; Accepted: 23 May 2024;
Published: 13 June 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Valvo, Vitale, Tigano, Evans, Morgan and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marco Tigano, Marco.Tigano@jefferson.edu; Rachel Evans, Rachel.evans2@astrazeneca.com; Meredith A. Morgan, mmccrack@med.umich.edu; Qiang Zhang, qiangz@med.umich.edu